K
Kenneth Pfarr
Researcher at University Hospital Bonn
Publications - 97
Citations - 3444
Kenneth Pfarr is an academic researcher from University Hospital Bonn. The author has contributed to research in topics: Onchocerca volvulus & Wolbachia. The author has an hindex of 30, co-authored 82 publications receiving 2725 citations. Previous affiliations of Kenneth Pfarr include University of Bonn & Bernhard Nocht Institute for Tropical Medicine.
Papers
More filters
Journal ArticleDOI
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke,Marco Pieroni,Tilmann Weber,Mark Brönstrup,Peter Hammann,Ludovic Halby,Paola B. Arimondo,Philippe Glaser,Bertrand Aigle,Helge B. Bode,Helge B. Bode,Rui Moreira,Yanyan Li,Andriy Luzhetskyy,Marnix H. Medema,Jean-Luc Pernodet,Marc Stadler,José R. Tormo,Olga Genilloud,Andrew W. Truman,Kira J. Weissman,Eriko Takano,Stefano Sabatini,Evi Stegmann,Heike Brötz-Oesterhelt,Wolfgang Wohlleben,Myriam Seemann,Martin Empting,Anna K. H. Hirsch,Brigitta Loretz,Claus-Michael Lehr,Alexander Titz,Jennifer Herrmann,Timo Jaeger,Silke Alt,Thomas Hesterkamp,Mathias Winterhalter,Andrea Schiefer,Kenneth Pfarr,Achim Hoerauf,Heather Graz,Michael Graz,Mika Lindvall,Savithri Ramurthy,Anders Karlén,Maarten van Dongen,Hrvoje Petković,Andreas Keller,Frédéric Peyrane,Stefano Donadio,Laurent Fraisse,Laura J. V. Piddock,Ian H. Gilbert,Heinz E. Moser,Rolf Müller +54 more
TL;DR: In this paper, the authors present a strategic blueprint to substantially improve our ability to discover and develop new antibiotics, and propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding.
Journal ArticleDOI
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
Achim Hoerauf,Sabine Specht,Marcelle Büttner,Kenneth Pfarr,Sabine Mand,Rolf Fimmers,Yeboah Marfo-Debrekyei,Peter Konadu,Alexander Yaw Debrah,Claudio Bandi,Norbert W. Brattig,Anna Albers,John Larbi,Linda Batsa,Mark J. Taylor,Ohene Adjei,Dietrich W. Büttner +16 more
TL;DR: Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.
Journal ArticleDOI
Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis.
Alexander Yaw Debrah,Sabine Mand,Sabine Specht,Yeboah Marfo-Debrekyei,Linda Batsa,Kenneth Pfarr,John Larbi,Bernard W. Lawson,Mark R Taylor,Ohene Adjei,Achim Hoerauf +10 more
TL;DR: A 6-wk regimen of antifilarial treatment with doxycycline against W. bancrofti showed a strong macrofilaricidal activity and reduction in plasma levels of VEGF-C/sVEGFR-3, the latter being associated with amelioration of supratesticular dilated lymphatic vessels and with an improvement of pathology in lymphatic filariasis patients.
Journal ArticleDOI
Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production.
Achim Hoerauf,Sabine Mand,Kerstin Fischer,Thomas Kruppa,Yeboah Marfo-Debrekyei,Alexander Yaw Debrah,Kenneth Pfarr,Ohene Adjei,Dietrich W. Büttner +8 more
TL;DR: Doxycycline is also effective in depleting Wolbachia from W. bancrofti and could render doxycycline treatment an additional tool for the treatment of microfilaria-associated diseases in banc roftian filariasis, such as tropical pulmonary eosinophilia and microfiluria.
Journal ArticleDOI
Filariasis and lymphoedema
TL;DR: As for the aberrant lymph vessel development, innate immune responses that are triggered by the filarial antigen ultimately result in the activation of vascular endothelial growth factors (VEGF), thus promoting lymph vessel hyperplasia as a first step to lymphoedema development.